Anivive (9/28/2021)

CB Partner Webinar {{webinarsregistrationpage::webinar_title}} {{webinarsregistrationpage::race_approved}} true 1 Credit Hour {{webinarsregistrationpage::hero_image}} {{webinarsregistrationpage::hero_image_self_hosted}} {{webinarsregistrationpage::hero_image_desktop_background_position}} {{webinarsregistrationpage::hero_image_mobile_background_position}} {{webinarsregistrationpage::hero_image_custom_padding}} {{webinarsregistrationpage::hero_image_custom_padding_mobile}} Anivive {{webinarsregistrationpage::supported_by}} {{webinarsregistrationpage::multiple_speakers}}

Thanks to faster diagnostics and new treatment options, primary care teams can play a bigger role in caring for canine lymphoma patients. For many veterinary oncologists with a weeks-long patient waitlist, this represents a welcome evolution in collaborative care. In this webinar, Dr. Clifford will share the diagnostics he likes to see from his referring clinics today. He’ll also review the mechanism of action, efficacy data, and clinical applications for LAVERDIA™-CA1 (verdinexor), a new oral therapeutic clients can use to treat lymphoma at home. Dr. Galligher will join the conversation to talk about best practices for treating canine lymphoma in primary care. Together, Dr. Clifford and Dr. Galligher will review treatment plans for patients waiting for chemotherapy and for those that decline referral.

{{webinarsregistrationpage::inside_the_webinar_2}} {{webinarsregistrationpage::inside_the_webinar_3}} Techniques to diagnose, stage, and grade canine lymphoma Which diagnostic tests inform patient-specific treatment protocols How SINE technology, the novel mechanism in LAVERDIA-CA1, works Where LAVERDIA-CA1 may fit in at your practice and how it differs from multiagent chemotherapy Best practices for collaborating with a veterinary oncologist on patient care {{webinarsregistrationpage::what_youll_learn_bullet_6}} Company Description

Anivive Lifesciences is a biotechnology company focused on developing first-in-class therapeutics for veterinary patients. Anivive’s commitment to using software to more effectively and efficiently develop new drugs helped bring LAVERDIA-CA1 to market and expand access to cancer care.

In adherence with RACE guidelines, CE certificates can only be distributed to individual registrants under the name used upon registration. Group viewers will not be eligible to receive multiple CE certificates.